Blood (whole blood) saves the lives of many patients with blood loss, and I was born thanks to a blood donor.
Plasma rehydrates severely dehydrated patients and is difficult to synthesize artificially.
Platelets can help hemophiliacs.
It can be said that blood and blood products are the necessities of human beings in the modern medical treatment, which is the sign of the moral development of human society, the manifestation of the spirit of mutual help, and the most personal social care.
If you have graduated from high school and are in good health, I hope you will donate blood!
If my answer is useful to you, I sincerely hope that you will be selected as the best, I'm a newbie who needs 20 points of encouragement! Thank you!
Question 2: What are the medical blood products included Blood products as a branch of biomedicine, the future prospects are also inevitable in modern biotechnology, industrial expansion and integration is an inevitable trend
There are several major categories, respectively, vaccines, bacteriophages Antibodies, antigens Biodiagnostic reagents
Question 3: How many blood products are there in the country There are blood product manufacturers in the country There are thirty-four domestic blood products manufacturers, more than twenty normal open, the annual plasma processing capacity of more than 100 tons of only ten. Since 1998, the State has required all blood product enterprises to adopt machine harvesting, which has increased the cost of each ton of albumin by nearly 10 million yuan. Coupled with the domestic economic downturn in the past two to three years, the demand for related products was insufficient, and it became more difficult for the enterprises to sell their products. The ex-factory price of the products of most of the enterprises was lower than that stipulated by the state, and the profit margin of the products declined. The key to the survival of such enterprises lies in the adoption of new technologies to reduce costs and the separation of more drug proteins from plasma through technological innovation to increase profits. In terms of production process, all domestic human blood albumin and human blood immunoglobulin-based products adopt low-temperature ethanol method; more than 20% of production units use press-filtering method instead of centrifugation for liquid-solid separation, which greatly improves the output of the products (mainly human blood albumin) and changes the production process from the open operation of centrifugal separation to the airtight operation of press-filtering method. In order to improve the safety of blood products, all blood products in China incorporate a one-step or two-step removal/inactivation process as required. In terms of product quality, the quality of human blood albumin produced in China has reached the level of similar products in the world; human blood immunoglobulin for intravenous injection has a complete range of IgG subclasses, complete Fc function, and some of the quality indexes of immunoglobulin (purity of the product, content of monomers and dimers as well as content of hepatitis B antibody) are higher than that of the European Pharmacopoeia; the quality of lyophilized human coagulation factor VIII concentrated preparation and lyophilized human thrombin complex is higher in quality compared with that of the European Pharmacopoeia. The quality of lyophilized human coagulation factor VIII concentrated preparation and lyophilized human prothrombin complex still has a gap in quality compared with the European Pharmacopoeia. Compared with foreign blood product enterprises, the main problems in the domestic blood product industry are: there are many production enterprises, but the production scale is small; the comprehensive utilization of blood is not enough; there is still a gap in the management of blood source and the enhancement of the safety of blood products. China's blood products industry is in a state of serious oversupply, the national theoretical plasma demand for 8,000 tons, while the overall domestic plasma collection in 2012 was only about 4,000 tons, the imbalance between supply and demand has led to a strong pattern of sellers in the blood products industry, creating a high degree of prosperity in the industry. According to the analysis of "China Blood Products Industry Production, Sales, Demand and Investment Forecast Analysis", there is a simple law in the blood products industry - the richer the product line, the higher the profit margin. Because the raw materials for producing blood products are the same batch of plasma, so if more products can be extracted from the same batch of plasma, the cost can be effectively diluted. The industry generally recognized model is to use albumin, static C and coagulation factor VIII as the main products to ensure the basic profit, and then other products (mainly special immunity, coagulation factor IX, fibrinogen, alpha-1 antitrypsin, PCC) to create additional profits. And this requires companies to have advanced technology that can effectively isolate as many types of proteins as possible from the same batch of plasma. With the significant increase in nutritional fees for plasma collectors in recent years, and rising costs in testing and transportation, the blood products industry faces the risk of rising comprehensive costs and declining product gross margins. Although the impact in this regard can be eliminated by raising prices in the short term, blood products are subject to a greater risk of downward price adjustments due to their basic entry into the national health insurance. Therefore, increasing technical investment, improving blood utilization and optimizing product structure is the primary task for future development. With the continuous improvement of the domestic medical level, the clinical application of blood products to improve the understanding of the domestic health care continue to improve, the domestic consumption of blood products in the structure of albumin will continue to decline, static C and specific immunoglobulin and other production ratio will continue to improve the consumption structure of blood products will continue to be optimized.
Question 4: What are the blood products? Red blood cells, blood stoops, platelets, albumin are also counted
In general, the regular channels are still safe
But some donors, if they have certain diseases
In a certain window period, the blood station can not be detected
Therefore, there is a risk of blood transfusion
Question 5: The conceptual stocks of blood products
The conceptual stocks of blood products
The conceptual stocks of blood products are not only the blood products, but also the blood products. What are the Hualan Bio 002007
Research Institutions: Southwest Securities
It is expected that the volume of plasma collection in 2017 exceeded 1,000 tons, consolidating the leading position in the industry.1) The company's existing 17 plasma stations, the number of which is second only to Shanghai Lesbian (002252) and Tiantan Bio (600161), is estimated to have a volume of 700 tons of plasma collection in 2015, second only to Shanghai Lesbian. After the Shizhu sub-station obtains the license for pulp collection, all six sub-stations in Chongqing can start formal pulp collection, and it is expected that the volume of pulp collection in Chongqing is expected to increase by more than 30%. With the potential of the existing plasma station tapping, the volume of plasma harvested in 2017 is expected to exceed 1,000 tons. 2) From the product line point of view, the company's existing human albumin, static human immunoglobulin, coagulation factor VIII, tetanus human immunoglobulin, human fibrinogen and other 11 varieties, for the current domestic product line is one of the most companies, the overall profitability is in the upper reaches of the industry.
Will enjoy the blood products industry volume and price improvement opportunities. 2015 June since the cancellation of the maximum retail price, blood products industry chain dividend release, the plasma station to expand the enthusiasm continued to improve. 1) from the plasma station set, 2014, 2015, the national newly approved plasma station of about 40, the recent approval of Chongqing, Guangdong and other places to speed up the approval of the plasma station in some provinces to approve the attitude of the positive changes. The company currently enjoys Chongqing, Henan plasma station resources, plasma station in the two places approved ability is strong, only Chongqing, there are still 9 counties have not set up the plasma station, Henan as a populous province has greater development potential. 2) From the product price point of view, in the supply can not be effectively alleviate the demand, in addition to the albumin can be imported from abroad at lower prices can not be raised prices, other products have a strong expectation of a price increase. Static C ex-factory price to maintain a steady upward trend, the future is expected to maintain the annual 10% -20% price increase, special exemptions, human fibrinogen and other small varieties of price elasticity. We believe that the blood products industry ushered in the boom cycle of volume and price, the company as the industry leader, has a huge performance improvement space.
WHO pre-certification is expected to promote the vaccine volume, early layout of the blue ocean market monoclonal antibody. The influenza vaccine has been certified by WHO, and the influenza vaccine will soon be certified by WHO, which is expected to enter the WHO vaccine procurement system with a scale of more than 1 billion US dollars, and to gain a foothold in the international market, and the foreign export will be a new growth point of the vaccine business. The joint venture subsidiary Hualan Genetic Engineering Co., Ltd. focuses on the monoclonal antibody business, Adalmu, Rituxan, Bevac, trastuzumab and other heavyweight varieties of 2014 sales of more than 6 billion U.S. dollars, the domestic generics are currently in the clinical stage, after the listing is expected to become a large variety of hundreds of millions of dollars, the future of the market space is larger.
Earnings forecast and investment advice. It is expected that the company's 2015-2017 EPS were 1.08 yuan, 1.30 yuan, 1.61 yuan, corresponding to the current P/E ratio of 39 times, 33 times, 26 times. We believe that the company is a blood products first-line enterprises, endogenous growth momentum is strong, will fully share the industry boom cycle dividends, give "buy" rating.
Burson-Marsteller 300294
Research Organization: Southwest Securities
Performance exceeded expectations, the price of blood products is the core reason. We previously predicted that the company's 2015 net profit of 134 million yuan (+29%), the performance forecast exceeded our expectations mainly because of the price increase of blood products to contribute to the performance. Since the Development and Reform Commission in June 2015 to cancel the maximum retail price restrictions, blood product companies have raised prices. At present, the company's static C price increase of nearly 20%, fiber original price increase is more than 100%, price increase and performance are beyond market expectations. The long-standing phenomenon of oversupply is the main driving force of the price of blood products, China's annual demand for plasma more than 8,000 tons, but the annual plasma harvesting capacity of only 6,000 tons or so, far from meeting market demand. Sub-products, albumin can be imported from abroad at lower prices, so there is basically no room for price increases; coagulation factor VIII is mainly paid by the medical insurance and therefore less room for price increases; static C use a large number of people involved in a wide range of people and therefore may not appear a substantial price increases; fibrinogen is a one-time use of drugs and drugs accounted for a small percentage of the main out-of-pocket expenses of the patient, the largest space for price increases. The company static C accounted for a small market share, mainly to follow the industry and gradually raise prices; but the fibrinogen market share of more than 40% and high technical barriers, with the market pricing power, the future there is also a huge space for price increases. With the gradual increase in the price of blood products, the company's revenue and profit will be substantial growth, to promote the performance of high-speed growth.
Strong ability to expand the plasma station, plasma harvesting volume to achieve leapfrog growth. 2014 the company has only five plasma station put into production, plasma harvesting volume is only about 130 tons, but by 2015 the company has ...... >>
Question 6: What are the listed companies of blood products Tiantan Bio's Chengdu Rongsheng Pharmaceutical's blood products accounted for almost half of Tiantan's profits.
In order, Hualan Bio, Shanghai Leslie, Tiantan Bio.
Now that Hualan's source of plasma is under some constraints, blood products are trending up.
Question 7: What are the blood products? What kind of enterprises can produce? Regulations on the Administration of Blood Products Chapter I General Provisions Article 1 In order to strengthen the management of blood products, prevention and control of blood-borne diseases, to ensure the quality of blood products, according to the Drug Administration Law and the Prevention and Control of Infectious Diseases Law, the enactment of these regulations. Article 2 These Regulations shall apply to the collection and supply of raw plasma and the production and operation of blood products within the territory of the People's Republic of China. Article 3 The health administrative department of the State Council shall supervise and manage the collection and supply of raw plasma and the production and operation of blood products throughout the country. The local people's *** health administrative departments at or above the county level shall exercise supervision and management over the collection and supply of raw plasma and the production and operation of blood products in their own administrative areas in accordance with the responsibilities stipulated in Article 30 of these Regulations. Chapter II Management of Raw Material Plasma Article 4 The State shall implement a system of unified planning and setting up of single blood collection stations. The health administrative department of the State Council shall, according to the approved demand for raw plasma for national production, formulate a general plan for the layout, number and scale of single plasma collection stations. The people's health administrative departments of provinces, autonomous regions and municipalities directly under the Central Government shall, in accordance with the overall plan, formulate plans for the setting up of single plasma collection stations and regional plans for the collection of plasma in their respective administrative regions, and report them to the health administrative department of the State Council for the record. Article 5 The single plasma collection stations shall be set up by the blood product production units or by the administrative departments of health of the people at the county level ***, and shall specialize in single plasma collection activities and have independent legal personality. No other unit or individual shall engage in the activity of single-collection plasma. Article 6 The establishment of a single plasma collection station must have the following conditions: (1) in line with the layout, number and scale of single plasma collection station planning; (2) with the collection of raw material plasma compatible health professionals and technicians; (3) with the collection of raw material plasma compatible with the premises and sanitary environment; (4) with identification of plasma supplier identification system; (5) with the collection of raw material plasma compatible with the single plasma collection machinery and other facilities. (E) with the collection of raw plasma machinery and other facilities appropriate to the collection of single plasma; (F) with the collection of raw plasma quality inspection of technical personnel and the necessary instruments and equipment. Article 7 The application for setting up a single plasma station, by the county-level people *** health administrative department for initial examination, by the district of the city, the Autonomous Prefecture people *** health administrative department or province, autonomous region people *** set up by the dispatching authorities of the health administrative organs for examination and consent, reported to the province, autonomous region, province directly under the Central Government *** people *** health administrative department for examination and approval; after examination meets the conditions, by the province, autonomous region, municipality people *** people *** health administrative department to issue "single plasma collection", "single plasma collection", and other facilities. The single plasma collection station can only screen and collect plasma from the plasma suppliers within the area designated by the health administrative department of the people's *** province, autonomous region or municipality directly under the Central Government. Article 8 The Single Plasma Collection License shall be valid for a specified period of time. Article 9 In a plasma collection area, only one single plasma collection station can be set up. It is strictly prohibited for a single plasma collection station to collect plasma from plasma suppliers and other persons not within the demarcated area. Article 10 single plasma collection stations must be plasma donors health checks; qualified by the county-level people *** health administrative departments to issue "plasma supply certificate. For plasma health inspection standards, by the State Council administrative department of health. Article 11 "plasma supply certificate" by the province, autonomous region, municipality directly under the Central People's *** health administrative department is responsible for the design and printing. Plasma supply certificate shall not be altered, forged or transferred. Article 12 Before collecting plasma, a single plasma collection station must identify the plasma supplier and verify his/her Plasma Supply Certificate, and only if there is no error in the identification can it carry out health examination and blood test according to the prescribed procedures; if the examination and test are qualified, it shall collect plasma in accordance with the relevant technical operation standards and procedures, and set up a file of plasma supplier's health examination and record of plasma supply; if the examination and test fail, the single plasma collection station shall seize the Plasma Supply Certificate and transfer it to another station. In case of unqualified examination and laboratory test, the single plasma collection station shall collect the "plasma supply certificate" and destroy it under the supervision of the local county-level people's *** health administrative department. It is strictly prohibited to collect plasma from those who do not have the Plasma Supply Certificate. Plasma collection technical operation standards and procedures, developed by the State Council administrative department of health. Article 13 A single plasma station can only supply raw plasma to a blood product production unit with which it has signed a quality responsibility statement, and it is strictly prohibited to supply raw plasma to any other unit. Article 14 The mono-collecting plasma station must use mono-collecting ...... >>
Question 8: What are the main blood component products The types of blood products include: (1) whole blood: ① fresh blood; ② stored blood; (2) component blood: ① plasma (fresh plasma, frozen plasma, preserved plasma); ② red blood cells (concentrated red blood cells, washed red blood cells, red blood cell suspensions);
(3) leukocyte concentrate suspensions; (4) platelet concentrate suspensions; ⑤ a variety of coagulation agents, such as prothrombin complexes, etc.; (3) other blood products: ① albumin fluid; ② fibrinogen; ③ anti-hemophilic globulin concentrates.